PT-141 10mg

A$70.00

Quality & Assurance

 

• COA available on every batch

• Fast Australia-wide dispatch

• Secure encrypted checkout

• Discreet, carefully packaged delivery

 


PT-141 (Bremelanotide) – 10 mg Research Peptide

 

 

NRG Peptide Kingdom | 99% Purity | Research Use Only

 

 

 

Product Overview

 

 

PT-141 (also known as Bremelanotide) is a synthetic melanocortin receptor agonist peptide widely studied for its effects on central nervous system signaling pathways, neuroreceptor modulation, and behavioral response mechanisms.

 

Within laboratory environments, PT-141 is primarily utilized to investigate melanocortin receptor activity (MC1R–MC5R), hypothalamic signaling pathways, neurotransmitter interaction models, and CNS-mediated physiological response patterns.

 

This compound is supplied strictly for controlled laboratory and in-vitro research applications.

 

⚠️ Not for human or veterinary use.

 

 

 

Key Features

 

 

  • 10 mg lyophilized PT-141 per vial
  • ≥ 99% purity (HPLC verified)
  • Synthetic melanocortin receptor agonist peptide
  • Research-grade formulation
  • Individually sealed sterile glass vial
  • Batch-specific Certificate of Analysis (COA) included
  • Manufactured for advanced neurochemical and receptor research

 

 

 

 

Intended Use

 

 

This product is supplied strictly for laboratory research use only (RUO).

 

Common research applications include:

 

  • Melanocortin receptor binding studies
  • CNS signaling pathway investigations
  • Neurotransmitter interaction modeling
  • Behavioral physiology research frameworks
  • Hormonal signaling cascade analysis
  • Pharmacodynamic profiling in vitro

 

 

Not approved for therapeutic, diagnostic, cosmetic, or veterinary use.

 

 

 

Regulatory Notice

 

 

For laboratory research use only. Not for human or veterinary administration. Not approved by the TGA, FDA, EMA, or any regulatory authority for therapeutic or diagnostic use. The purchaser assumes all responsibility for lawful handling, storage, and application.